4473 Willow Road, Suite 100
6 articles with NeoTract Inc.
NeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage or of Treatment Options
NeoTract Announces Japanese Regulatory Approval for UroLift® System for Treatment of Enlarged Prostate
NeoTract today announced the Company has received Shonin approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the UroLift® System for the treatment of benign prostatic hyperplasia (BPH).
NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England
A new Government scheme announced today selects the UroLift® System as one of seven innovations across all specialisms that are the most transformative for NHS patients
NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate
Data in Diverse Patient Populations from Three Continents Presented at World Congress of Endourology 2018 Annual Conference
NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care
Studies Show Significantly Reduced Complications, Improved Service Capacity, and Decreased Costs
NeoTract Announces Multiple Data Presentations from Studies of UroLift® System Treatment for Enlarged Prostate at the World Congress of Endourology
Chief Technical Officer Ted Lamson to Receive Prestigious Industry Award for Innovation